Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

505.40INR
20 Apr 2018
Change (% chg)

Rs-3.40 (-0.67%)
Prev Close
Rs508.80
Open
Rs508.50
Day's High
Rs509.00
Day's Low
Rs502.50
Volume
127,619
Avg. Vol
590,889
52-wk High
Rs667.75
52-wk Low
Rs433.15

Select another date:

Wed, Apr 18 2018

BRIEF-Sun Pharmaceutical Industries' Unit Raises Stake In Ranbaxy Malaysia

* UNIT RAISED STAKE IN RANBAXY MALAYSIA VIA FURTHER PURCHASE OF 394,404 SHARES OF RANBAXY MALAYSIA

BRIEF-Sun Pharmaceutical Industries Gets U.S. FDA Nod Of ILUMYA (Tildrakizumab-Asmn)

* CO GETS U.S. FDA APPROVAL OF ILUMYA (TILDRAKIZUMAB-ASMN) FOR TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text - http://bit.ly/2HRX8j1 Further company coverage:

BRIEF-Sun Pharmaceutical Industries Says U.S. FDA Issued Form 483 With 3 Observations For Halol Facility

* SUN PHARMACEUTICAL INDUSTRIES -U.S. FDA CONDUCTED GMP INSPECTION OF HALOL FACILITY (GUJARAT, INDIA) FROM FEBRUARY 12-23, 2018

UPDATE 1-India's Sun Pharma quarterly profit plunges on weak U.S. sales

* Profit hit by one-time deferred tax adjustment (Adds details)

BRIEF-Sun Pharma Industries Says Qtrly US Finished Dosage Sales Down 35 Pct

* SAYS US FINISHED DOSAGE SALES DURING QUARTER AT US$ 328 MILLION, DOWN 35 PERCENT OVER Q3 LAST YEAR Source text for Eikon: Further company coverage:

India's Sun Pharma Q3 profit slides 75 pct, misses estimates

Feb 14 India's largest drugmaker Sun Pharmaceutical Industries Ltd reported on Wednesday a 75 percent drop in net profit in the quarter ending Dec. 31, well below analysts' estimates.

BRIEF-India's Sun Pharmaceutical Industries Dec-Qtr Consol Profit Down 75 Pct

* DEC QUARTER CONSOL NET PROFIT AFTER TAX 3.65 BILLION RUPEES VERSUS PROFIT OF 14.72 BILLION RUPEES LAST YEAR

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

BRIEF-Sun Pharmaceutical Industries Announces U.S FDA Acceptance Of NDA For OTX-101

* ANNOUNCES U.S FDA ACCEPTANCE OF NDA FOR OTX-101 Source text - http://bit.ly/2BDUZEZ Further company coverage:

BRIEF-Sun Pharmaceutical Industries Reports 12.3 Percent Stake In Scpharmaceuticals As Of November 21

* SUN PHARMACEUTICAL INDUSTRIES LIMITED REPORTS 12.3 PERCENT STAKE IN SCPHARMACEUTICALS INC AS OF NOVEMBER 21 - SEC FILING‍​

Select another date: